Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...

Pharmaceutical company Sarepta Therapeutics is taking Wall Street by surprise today, falling to $64.75 and marking a -8.0% ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Here are some quick facts to get you started if you are interested in the stock: Sarepta Therapeutics has logged a -41.7% 52 week change, compared to 7.5% for the S&P 500 SRPT has an average analyst ...

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...